Tessa Hagens
Promovendus
- Naam
- T.M.S. Hagens MSc
- Telefoon
- 071 5275706
- t.m.s.hagens@lacdr.leidenuniv.nl
- ORCID iD
- 0009-0007-8381-0111
Voor meer informatie zie Engelse profielpagina.
Promovendus
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Toxicology
- Bonanini F.F., Dinkelberg R., Torregrosa M.C., Kortekaas N., Hagens T.M.S., Treillard S., Kurek D., Duinen V. van, Vulto P. & Bircsak K. (2025), A microvascularized in vitro liver model for disease modeling and drug discovery, Biofabrication 17(1): 015007.
- Bahtiri S., Hagens T.M.S., Water B. van de & Niemeijer M.C. (2025), Mechanism-based drug safety testing using innovative in vitro liver models: from DILI prediction to idiosyncratic DILI liability assessment, Expert Opinion on Drug Metabolism & Toxicology 21(7): 769-787.
- Bahtiri S., Hagens T.M.S., Water B. van de & Niemeijer M.C. (2025), Mechanism-based drug safety testing using innovative in vitro liver models: from DILI prediction to idiosyncratic DILI liability assessment, Expert Opinion on Drug Metabolism & Toxicology 21(7): 769-787.
- Bergonzini C., Gregori A., Hagens T.M.S., Noord V.E. van der, Water B. van de, Zweemer A.J.M., Coban B., Capula M., Mantini G., Botto A., Finamore F., Garajova I., McDonnell L.A., Schmidt T., Giovannetti E. & Danen E.H.J. (2024), ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells, Journal of Experimental & Clinical Cancer Research 43: 4.